Stock 08HH SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Deutsche Boerse AG

Equities

08HH

CNE100001M79

Delayed Deutsche Boerse AG
Other stock markets
 02:13:45 12/06/2024 pm IST 		5-day change 1st Jan Change
1.636 EUR +2.89% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +3.22% -14.59%
07/06 Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3% MT
03/06 Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7% MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company is in debt and has limited leeway for investment
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Stock Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
-14.59% 7.92B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.65% 780B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.76% 627B
B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.97% 334B
B-
ABBVIE INC. Stock AbbVie Inc.
+6.92% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.60% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-0.41% 217B
A+
NOVARTIS AG Stock Novartis AG
+11.54% 214B
B-
AMGEN INC. Stock Amgen Inc.
+4.39% 161B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.53% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. 08HH Stock
  5. Ratings Shanghai Fosun Pharmaceutical (Group) Co., Ltd.